基本信息
浏览量:162
职业迁徙
个人简介
Extensive track record in discovery of biotherapeutics and translation from pre-clinical candidates to FDA-approval phase, including building diverse portfolios from which >60 drug candidates have progressed to the clinic.
Comprehensive experience in advancing innovative and emerging technologies, such as Fc engineered naked mAbs, effector function enhanced mAbs, antibody-cytokine fusion & antibody-drug conjugates, recombinant fusion proteins, bispecific molecules, checkpoint inhibitors, immunostimulatory molecules, adoptive/CAR cell therapies (including donor-derived & iPSC approaches), and technologies that are still evolving.
Respected division leader with expertise in building and leading teams across the entire spectrum of drug development, from initial discovery to IND and patent filing, safety, PK/PD, CMC, regulatory, and early-phase clinical trials. Experience in working in a highly matrixed environment, including chairing and participating in high-level company committees responsible for making go/no go decisions. Chaired numerous joint-steering committees for academic and industry collaborations, interacting with advisors, KOLs, SRB, board, executive committee etc.
Comprehensive experience in advancing innovative and emerging technologies, such as Fc engineered naked mAbs, effector function enhanced mAbs, antibody-cytokine fusion & antibody-drug conjugates, recombinant fusion proteins, bispecific molecules, checkpoint inhibitors, immunostimulatory molecules, adoptive/CAR cell therapies (including donor-derived & iPSC approaches), and technologies that are still evolving.
Respected division leader with expertise in building and leading teams across the entire spectrum of drug development, from initial discovery to IND and patent filing, safety, PK/PD, CMC, regulatory, and early-phase clinical trials. Experience in working in a highly matrixed environment, including chairing and participating in high-level company committees responsible for making go/no go decisions. Chaired numerous joint-steering committees for academic and industry collaborations, interacting with advisors, KOLs, SRB, board, executive committee etc.
研究兴趣
论文共 185 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer research communicationsno. 3 (2022): 146-157
TRENDS IN BIOTECHNOLOGYno. 3 (2021): 298-310
Cam V. Holland, John Kehoe, Judith Hailey,Rupesh Nanjunda,Eilyn Lacy,Robin Ernst,Di Zhang, Sam Wu,Alexey Teplyakov,Weimin Li,Michelle Kinder, Edward W. Thompson,
Karla R Wiehagen, Natasha M Girgis, Douglas H Yamada, Andressa A Smith, Szeman Ruby Chan,Iqbal S Grewal,Michael Quigley,Raluca I Verona
mag(2015)
引用23浏览0引用
23
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn